{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:33:22Z","timestamp":1791614002632,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["fellowship recipient"],"award-info":[{"award-number":["fellowship recipient"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006694","name":"Associazione Italiana Contro le Leucemie - Linfomi e Mieloma","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100006694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2013 N.14346"],"award-info":[{"award-number":["IG 2013 N.14346"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,10,1]]},"DOI":"10.1038\/s41416-019-0557-8","type":"journal-article","created":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T23:02:24Z","timestamp":1567378944000},"page":"567-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma"],"prefix":"10.1038","volume":"121","author":[{"given":"Martina","family":"Magni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Biancon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rizzitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cavan\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Paolizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Dugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-1757","authenticated-orcid":false,"given":"Cristiana","family":"Carniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,2]]},"reference":[{"key":"557_CR1","doi-asserted-by":"publisher","first-page":"1179545X1770586","DOI":"10.1177\/1179545X17705863","volume":"10","author":"C Hildyard","year":"2017","unstructured":"Hildyard, C., Shiekh, S., Browning, J. & Collins, G. Toward a biology-driven treatment strategy for peripheral T-cell lymphoma. Clin. Med. Insights Blood Disord. 10, 1179545X1770586 (2017).","journal-title":"Clin. Med. Insights Blood Disord."},{"key":"557_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","volume":"129","author":"A Broccoli","year":"2017","unstructured":"Broccoli, A. & Zinzani, P. L. Peripheral T-cell lymphoma, not otherwise specified. Blood 129, 1103\u20131112 (2017).","journal-title":"Blood"},{"key":"557_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pathog.2016.02.002","volume":"3","author":"F Maura","year":"2016","unstructured":"Maura, F., Dodero, A., Carniti, C. & Bolli, N. Biology of peripheral T cell lymphomas\u2014 not otherwise specified: is something finally happening? Pathogenesis 3, 9\u201318 (2016).","journal-title":"Pathogenesis"},{"key":"557_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/bjh.13855","volume":"172","author":"RH Advani","year":"2016","unstructured":"Advani, R. H., Ansell, S. M., Lechowicz, M. J., Beaven, A. W., Loberiza, F., Carson, K. R. et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. Br. J. Haematol. 172, 535\u2013544 (2016).","journal-title":"Br. J. Haematol."},{"key":"557_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh, M., Tr\u00fcmper, L., Kloess, M., Schmits, R., Feller, A. C., Rudolph, C. et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104, 626\u2013633 (2004).","journal-title":"Blood"},{"key":"557_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.beha.2018.07.010","volume":"31","author":"N Khan","year":"2018","unstructured":"Khan, N., Ozkaya, N., Moskowitz, A., Dogan, A. & Horwitz, S. Peripheral T-cell lymphoma\u2014are we making progress? Best Pract. Res. Clin. Haematol. 31, 306\u2013314 (2018).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"557_CR7","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","volume":"19","author":"J Rodriguez","year":"2001","unstructured":"Rodriguez, J., Munsell, M., Yazji, S., Hagemeister, F. B., Younes, A., Andersson, B. et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J. Clin. Oncol. 19, 3766\u20133770 (2001).","journal-title":"J. Clin. Oncol."},{"key":"557_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","volume":"151","author":"A Simon","year":"2010","unstructured":"Simon, A., Peoch, M., Casassus, P., Deconinck, E., Colombat, P., Desablens, B. et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br. J. Haematol. 151, 159\u2013166 (2010).","journal-title":"Br. J. Haematol."},{"key":"557_CR9","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini, A., Zaja, F., Patti, C., Billio, A., Specchia, M. R., Tucci, A. et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110, 2316\u20132323 (2007).","journal-title":"Blood"},{"key":"557_CR10","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/leu.2014.79","volume":"28","author":"P Corradini","year":"2014","unstructured":"Corradini, P., Vitolo, U., Rambaldi, A., Miceli, R., Patriarca, F., Gallamini, A. et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 28, 1885\u20131891 (2014).","journal-title":"Leukemia"},{"key":"557_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrd2135","volume":"5","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian, H., Jabbour, E., Grimley, J. & Kirkpatrick, P. Dasatinib. Nat. Rev. Drug Discov. 5, 717\u2013718 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"557_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40265-016-0677-x","volume":"77","author":"GM Keating","year":"2017","unstructured":"Keating, G. M. Dasatinib: a review in chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia. Drugs 77, 85\u201396 (2017).","journal-title":"Drugs"},{"key":"557_CR13","first-page":"1361","volume":"2","author":"RM Mohammad","year":"2003","unstructured":"Mohammad, R. M., Al-Katib, A., Aboukameel, A., Doerge, D. R., Sarkar, F. & Kucuk, O. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol. Cancer Ther. 2, 1361\u20131368 (2003).","journal-title":"Mol. Cancer Ther."},{"key":"557_CR14","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/bioinformatics\/btn224","volume":"24","author":"P Du","year":"2008","unstructured":"Du, P., Kibbe, W. A. & Lin, S. M. lumi: a pipeline for processing Illumina microarray. Bioinformatics 24, 1547\u20131548 (2008).","journal-title":"Bioinformatics"},{"key":"557_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2202\/1544-6115.1027","volume":"3","author":"GK Smyth","year":"2004","unstructured":"Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 1\u201325 (2004).","journal-title":"Stat. Appl. Genet. Mol. Biol."},{"key":"557_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"557_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1\u201313 (2009).","journal-title":"Nucleic Acids Res"},{"key":"557_CR18","first-page":"4950","volume":"6","author":"RM Mohammad","year":"2000","unstructured":"Mohammad, R. M., Wall, N. R., Dutcher, J. A. & Al-Katib, A. M. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin. Cancer Res. 6, 4950\u20134956 (2000).","journal-title":"Clin. Cancer Res."},{"key":"557_CR19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/nbm.1250","volume":"21","author":"SC Lee","year":"2008","unstructured":"Lee, S. C., Huang, M. Q., Nelson, D. S., Pickup, S., Wehrli, S., Adegbola, O. et al. In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft. NMR Biomed. 21, 723\u2013733 (2008).","journal-title":"NMR Biomed"},{"key":"557_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4614-7411-1_33","volume-title":"Oxygen Transport to Tissue XXXV","author":"He. N. Xu","year":"2013","unstructured":"Xu, H. N., Mir, T. A., Lee, S. C., Feng, M., Farhad, N., Choe, R. et al. Mapping the redox state of CHOP-treated non-hodgkin\u2019s lymphoma xenografts in mice. In: Van Huffel, S., Naulaers, G., Caicedo, A., Bruley, D.F., Harrison, D.K. (eds) Oxygen Transport to Tissue XXXV. Advances in Experimental Medicine and Biology, vol 789. (Springer, New York, NY 2013)."},{"key":"557_CR21","doi-asserted-by":"publisher","first-page":"7383","DOI":"10.1158\/1078-0432.CCR-11-1762","volume":"17","author":"TA Cheema","year":"2011","unstructured":"Cheema, T. A., Kanai, R., Kim, G. W., Wakimoto, H., Passer, B., Rabkin, S. D. et al. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin. Cancer Res. 17, 7383\u20137393 (2011).","journal-title":"Clin. Cancer Res."},{"key":"557_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2967\/jnumed.115.158881","volume":"57","author":"L Gao","year":"2016","unstructured":"Gao, L., Liu, H., Sun, X., Gao, D., Zhang, C., Jia, B. et al. Molecular imaging of post-src inhibition tumor signatures for guiding dasatinib combination therapy. J. Nucl. Med. 57, 321\u2013326 (2016).","journal-title":"J. Nucl. Med."},{"key":"557_CR23","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/leu.2014.192","volume":"28","author":"DL Petersen","year":"2014","unstructured":"Petersen, D. L., Krejsgaard, T., Berthelsen, J., Fredholm, S., Willerslev-Olsen, A., Sibbesen, N. A. et al. B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL). Leukemia 28, 2109\u20132112 (2014).","journal-title":"Leukemia"},{"key":"557_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","volume":"6","author":"A Emadi","year":"2009","unstructured":"Emadi, A., Jones, R. J. & Brodsky, R. A. Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6, 638\u2013647 (2009).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"557_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/ajh.24203","volume":"91","author":"RA Wilcox","year":"2016","unstructured":"Wilcox, R. A. A three-signal model of T-cell lymphoma pathogenesis. Am. J. Hematol. 91, 113\u2013122 (2016).","journal-title":"Am. J. Hematol."},{"key":"557_CR26","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1242\/jcs.042762","volume":"122","author":"M Huse","year":"2009","unstructured":"Huse, M. The T-cell-receptor signaling network. J. Cell Sci. 122, 1269\u20131273 (2009).","journal-title":"J. Cell Sci."},{"key":"557_CR27","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/sj.onc.1204224","volume":"20","author":"W Ma","year":"2001","unstructured":"Ma, W., Xia, C., Ling, P., Qiu, M., Luo, Y., Tan, T.-H. et al. Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes. Oncogene 20, 1703\u20131714 (2001).","journal-title":"Oncogene"},{"key":"557_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/intimm\/14.5.445","volume":"14","author":"M Nikolova","year":"2002","unstructured":"Nikolova, M., Marie-Cardine, A., Boumsell, L. & Bensussan, A. BY55\/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression. Int. Immunol. 14, 445\u2013451 (2002).","journal-title":"Int. Immunol."},{"key":"557_CR29","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1182\/blood-2009-08-239483","volume":"115","author":"F-T Liu","year":"2010","unstructured":"Liu, F.-T., Giustiniani, J., Farren, T., Jia, L., Bensussan, A., Gribben, J. G. et al. CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. Blood 115, 3079\u20133088 (2010).","journal-title":"Blood"},{"key":"557_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/intimm\/dxm005","volume":"19","author":"M Rabot","year":"2007","unstructured":"Rabot, M., El Costa, H., Polgar, B., Marie-Cardine, A., Aguerre-Girr, M., Barakonyi, A. et al. CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. Int. Immunol. 19, 401\u2013409 (2007).","journal-title":"Int. Immunol."},{"key":"557_CR31","doi-asserted-by":"publisher","unstructured":"Gorentla, B. K. & Zhong, X.-P. T cell receptor signal transduction in T lymphocytes. J. Clin. Cell Immunol. 2012(Suppl 12), 5 (2012). \n                    https:\/\/doi.org\/10.4172\/2155-9899.S12-005\n                    \n                  .","DOI":"10.4172\/2155-9899.S12-005"},{"key":"557_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14290","volume":"8","author":"F Cayrol","year":"2017","unstructured":"Cayrol, F., Praditsuktavorn, P., Fernando, T. M., Kwiatkowski, N., Marullo, R., Calvo-Vidal, M. N. et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nat. Commun. 8, 14290 (2017).","journal-title":"Nat. Commun."},{"key":"557_CR33","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","volume":"17","author":"JC Montero","year":"2011","unstructured":"Montero, J. C., Seoane, S., Ocana, A. & Pandiella, A. Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin. Cancer Res. 17, 5546\u20135552 (2011).","journal-title":"Clin. Cancer Res."},{"key":"557_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","volume":"12","author":"GM Keating","year":"2017","unstructured":"Keating, G. M. Sorafenib: a review in hepatocellular carcinoma. Target Oncol. 12, 243\u2013253 (2017).","journal-title":"Target Oncol"},{"key":"557_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835\u2013844 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"557_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2217\/fon-2017-0298","volume":"14","author":"N Curto-Garcia","year":"2018","unstructured":"Curto-Garcia, N. & Harrison, C. N. An updated review of the JAK1\/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms. Future Oncol. 14, 137\u2013150 (2018).","journal-title":"Future Oncol"},{"key":"557_CR37","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1016\/j.molimm.2007.02.022","volume":"44","author":"E-Y So","year":"2007","unstructured":"So, E.-Y., Oh, J., Jang, J.-Y., Kim, J.-H. & Lee, C.-E. Ras\/Erk pathway positively regulates Jak1\/STAT6 activity and IL-4 gene expression in Jurkat T cells. Mol. Immunol. 44, 3416\u20133426 (2007).","journal-title":"Mol. Immunol."},{"key":"557_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero, T., Couronn\u00e9, L., Khiabanian, H., Kim, M.-Y., Ambesi-Impiombato, A., Perez-Garcia, A. et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet. 46, 166\u2013170 (2014).","journal-title":"Nat. Genet."},{"key":"557_CR39","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1097\/PAS.0000000000000309","volume":"38","author":"C Agostinelli","year":"2014","unstructured":"Agostinelli, C., Rizvi, H., Paterson, J., Shende, V., Akarca, A. U., Agostini, E. et al. Intracellular TCR-signaling pathway. Am. J. Surg. Pathol. 38, 1349\u20131359 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"557_CR40","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science 263, 1281\u20131284 (1994).","journal-title":"Science"},{"key":"557_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.leu.2404045","volume":"20","author":"B Streubel","year":"2006","unstructured":"Streubel, B., Vinatzer, U., Willheim, M., Raderer, M. & Chott, A. Novel t(5;9)(q33; q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 20, 313\u2013318 (2006).","journal-title":"Leukemia"},{"key":"557_CR42","first-page":"735","volume":"464","author":"J Somja","year":"2014","unstructured":"Somja, J., Bisig, B., Bonnet, C., Herens, C., Siebert, R. & de Leval, L. Peripheral T-cell lymphoma with t(6;14)(p25; q11.2) translocation presenting with massive splenomegaly. Virchows Arch. 464, 735\u2013741 (2014).","journal-title":"Virchows Arch"},{"key":"557_CR43","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/leu.2008.320","volume":"23","author":"AL Feldman","year":"2009","unstructured":"Feldman, A. L., Law, M., Remstein, E. D., Macon, W. R., Erickson, L. A., Grogg, K. L. et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 23, 574\u2013580 (2009).","journal-title":"Leukemia"},{"key":"557_CR44","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1182\/blood-2017-11-764357","volume":"131","author":"JS Van Arnam","year":"2018","unstructured":"Van Arnam, J. S., Lim, M. S. & Elenitoba-Johnson, K. S. J. Novel insights into the pathogenesis of T-cell lymphomas. Blood 131, 2320\u20132330 (2018).","journal-title":"Blood"},{"key":"557_CR45","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois, D., Dobay, M. P. D., Morin, R. D., Lemonnier, F., Missiaglia, E., Juilland, M. et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 128, 1490\u20131502 (2016).","journal-title":"Blood"},{"key":"557_CR46","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal, J., Wright, G., Wang, C., Rosenwald, A., Gascoyne, R. D., Weisenburger, D. D. et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123, 2915\u20132923 (2014).","journal-title":"Blood"},{"key":"557_CR47","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/bjh.15702","volume":"184","author":"JM Umakanthan","year":"2019","unstructured":"Umakanthan, J. M., Iqbal, J., Batlevi, C. L., Bouska, A., Smith, L. M., Shostrom, V. et al. Phase I\/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. Br. J. Haematol. 184, 744\u2013752 (2019).","journal-title":"Br. J. Haematol."},{"key":"557_CR48","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/sj.onc.1203877","volume":"19","author":"JT Parsons","year":"2000","unstructured":"Parsons, J. T., Martin, K. H., Slack, J. K., Taylor, J. M. & Weed, S. A. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 19, 5606\u20135613 (2000).","journal-title":"Oncogene"},{"key":"557_CR49","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1242\/jcs.039446","volume":"122","author":"S Huveneers","year":"2009","unstructured":"Huveneers, S. & Danen, E. H. J. Adhesion signaling-crosstalk between integrins, Src and Rho. J. Cell Sci. 122, 1059\u20131069 (2009).","journal-title":"J. Cell Sci."},{"key":"557_CR50","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099\u20137109 (2004).","journal-title":"Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0557-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0557-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0557-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:38Z","timestamp":1684616738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0557-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,2]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,10,1]]}},"alternative-id":["557"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0557-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,2]]},"assertion":[{"value":"7 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal studies were approved by the Italian Ministry of Health (831\/2016-PR), according to the Italian law and in compliance with international policies and guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Associazione Italiana contro le Leucemie-Linfomi e mieloma (AIL), Associazione Italiana Ricerca Cancro (AIRC, IG 2013 N.14346). MM was recipient of Umberto Veronesi Foundation fellowship.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data generated during the current study are available from the corresponding author upon reasonable request. Gene expression data has been deposited in the NCBI Gene Expression Omnibus database, accession number GSE129289.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}